D apsone (4-4′-sulfonyldianiline), which was first synthesized in 1908, 1 is both an antibiotic and an antiinflammatory agent. Dapsone alone or in combination with other drugs has been used for the prevention and treatment of infectious diseases (e.g., leprosy, malaria, and actinomycetoma, as well as Pneumocystis jirovecii pneumonia in persons with human immunodeficiency virus [HIV] infection) and chronic inflammatory diseases characterized by the infiltration of neutrophils or eosinophils (e.g., dermatitis herpetiformis, linear IgA dermatosis, subcorneal pustular dermatosis, and erythema elevatum diutinum). 2, 3 About 0.5 to 3.6% of persons treated with dapsone have a drug hypersensitivity syndrome, 3-5 which was first described by Lowe and Smith 6 in 1949 and termed "dapsone hypersensitivity syndrome" 7 in 1951. The syndrome is a severe idiosyncratic drug reaction characterized by the clinical triad of fever, rash, and systemic involvement (most commonly of the liver and the hematologic system), which can cause severe organ dysfunction. The dapsone hypersensitivity syndrome is usually manifested 4 to 6 weeks after the initiation of therapy.
With the introduction of multidrug therapy for leprosy worldwide and with the use of dapsone in chemoprophylaxis for P. jirovecii pneumonia in patients with HIV infection, the incidence of the dapsone hypersensitivity syndrome may have increased. On the basis of a recent systematic review of the published epidemiologic studies, the estimated prevalence of the dapsone hypersensitivity syndrome is 1.4%, and the associated mortality is 9.9%. 8 According to the most recent study in the Chinese population, the incidence rate and mortality are 1.0% and 11.1%, respectively. 9 However, to date, there are no tests to predict the risk of the dapsone hypersensitivity syndrome.
Genetic factors have been shown to play an important role in drug-induced hypersensitivity reactions. For example, the HLA-B*15:02 allele was identified as an important predictor of the risks of carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in the population of Southeast Asia. 10 Clinical testing for this allele led to decreases in the incidence of each of these disorders in the Taiwanese population. 11 Recently, a genomewide association study linked the HLA-A*31:01 allele with carbamazepine-induced hypersensitivity reactions in the European population. 12 This finding highlighted the genetic heterogeneity of drug-induced hypersensitivity among ethnic populations and may facilitate the development of a diagnostic test for this potentially life-threatening condition in the European population.
To identify the genetic risk factors for the dapsone hypersensitivity syndrome, we performed a genomewide association study in the Chinese population, comparing patients with leprosy in whom the dapsone hypersensitivity syndrome developed after the initiation of treatment (case patients) with those in whom the syndrome did not develop (controls).
ME THODS

Study Participants
A total of 77 case patients (39 patients in the discovery analysis and 38 in the replication analysis) participated in this study, all of whom were patients with leprosy who had survived the dapsone hypersensitivity syndrome and were of Chinese descent. All received dapsone as part of multidrug therapy, and the dapsone hypersensitivity syndrome was diagnosed on the basis of the criteria proposed by Richardus and Smith. 13 Controls included 2064 patients (955 patients in the discovery analysis and 1109 in the replication analysis) who had been cured of leprosy after treatment with dapsone as part of multidrug therapy for at least 6 months but whose status with respect to the dapsone hypersensitivity syndrome could not be determined owing to insufficient medical information. The case patients and controls in both the discovery and replication analyses were matched for geographic origin and ethnic group. The demographic and clinical characteristics of the two groups are provided in Table 1 . Healthy persons of Chinese descent were assessed in order to estimate the allele frequency of HLA-B*13:01 in the Chinese population, including 951 persons from Guangdong Province, 523 from Shandong Province, and 470 from Yunnan Province. The study was approved by the institutional review board at the Shandong Provincial Institute of Dermatology and Venereology. Written informed consent was obtained from all participants. All the authors vouch for the accuracy and completeness of the data.
Human660W-Quad BeadChips, and the healthy persons from Guangdong were genotyped with the use of Illumina Human610-Quad BeadChips. 14 After quality-control measures were implemented, a total of 430,276 single-nucleotide polymorphisms (SNPs) in 39 case patients and 833 controls were used in the genomewide discovery analysis of association. For the test of replication, 24 selected non-major histocompatibility complex (MHC) SNPs were successfully genotyped in an additional 31 case patients and 1089 controls with the use of the Sequenom MassARRAY platform.
All association analyses were performed with the use of logistic regression with an additive model of inheritance (log-additive test) by means of PLINK software, 15 version 1.07. Because the case patients and controls were well matched genetically (Fig. S1 in the Supplementary Appendix, available with the full text of this article at NEJM.org), the association analysis was performed without controlling for population stratification. The discovery and replication samples were treated as independent samples in the combined analysis. Heterogeneity was assessed with the use of Cochran's Q statistic and quantified by calculating the I 2 statistic.
HLA Allele Imputation, Sequencing, and Association Analysis
Imputation of classical HLA alleles and amino acid variants of HLA (whose haplotypes defined the classical alleles) was performed with the use of Beagle software 16 and the reference panel from the HapMap dataset of Han Chinese in Beijing (CHB) and Japanese in Tokyo (JPT). 17, 18 Association was tested with the use of both the imputed classical alleles (at two-digit or fourdigit resolution) of HLA class I molecules (A, B, and C) and class II molecules (DQA1, DQB1, and DRB1) and the amino acid variants. The sequencing analysis of HLA-B and HLA-C molecules was performed with the use of the Roche 454 GS FLX platform. HLA alleles were identified at a four-digit resolution by means of HLA Caller, 19 as implemented in the Genome Analysis Toolkit.
Additional information regarding the diagnostic criteria for the dapsone hypersensitivity syndrome; genotyping, quality control, and analysis of population structure in the genomewide discovery analysis; the selection of SNPs for the replication test; and the imputation, sequencing, and association analysis of HLA alleles is provided in the Supplementary Appendix. (10) 182 (22) 2 (5) 5 (2) 6 (8) 187 (18) Other 7 (18) 7 (1) 7 (18) 25 (12) 14 (18) 32 (3) Indication for dapsone therapy for leprosy We imputed classical HLA alleles and amino acid positions as well as untyped SNPs within the MHC region in the discovery samples. A total of 66 classical HLA alleles imputed at two-digit resolution, 118 classical HLA alleles imputed at four-digit resolution, 309 amino acid substitution variants of HLA, and 4206 untyped SNPs, together with the 4636 genotyped SNPs, were tested for association with the dapsone hypersensitivity syndrome. Of the 309 amino acid variants, 238 were biallelic and 71 were multiallelic. For each multiallelic variant, association was analyzed with the use of a biallelic test of every possible grouping of amino acids, for a total of 497 tests across the 309 amino acid variants.
Of the imputed SNPs, only rs2844586 showed a stronger association (odds ratio, 14.77; P = 2.50×10 −15 ) than did rs2844573, but the two SNPs were correlated (D′ = 0.764, r 2 = 0.26). Much stronger associations were discovered at HLA-B*13:01 (odds ratio, 21.67; P = 2.04×10 −16 ) and HLA-C*03:04 (odds ratio, 13.43; P = 1.84×10 −14 ) (Fig. 1A and Table 2 ). These two HLA alleles were in linkage disequilibrium (D′ = 0.93, r 2 = 0.74). Controlling for HLA-B*13:01 eliminated the effect of HLA-C*03:04 (adjusted P = 0.76), but controlling for HLA-C*03:04 did not fully eliminate the effect of HLA-B*13:01 (adjusted P = 5.16×10 −5 ; adjusted odds ratio, 17.92). The two-digit classical HLA-B*13 allele also showed an association, but it was much weaker than the association at HLA-B*13:01 (Table S1 in the Supplementary Appendix).
Of the 497 tests for association across all 309 amino acid variants, 18 showed an association (P<1×10 −4 for all comparisons), with the strongest association at a variant encoding leucine residue at position 145 (Leu145) of HLA-B*13:01 (odds ratio, 8.41; P = 5.11×10 −13 ), but all these associations were weaker than the association at HLA-B*13:01 (Table S1 in the Supplementary Appendix). Adjustment for HLA-B*13:01 eliminated the extensive associations observed within the whole MHC region, including the strong associations at rs2844573, rs2844586, and Leu145 ( Fig. 1B) . Taken together, these results indicate that HLA-B*13:01 is the primary risk variant for the dapsone hypersensitivity syndrome within the MHC region.
Replication Analysis
None of the 24 non-MHC SNPs selected for the replication analysis showed a significant genomewide association with the dapsone hypersensitivity syndrome when the discovery and replication samples were analyzed together, although a consistent association was observed at 3 SNPs (rs991773, rs2280899, and rs13187034) with nominal significance (P<0.05) when the replication sample alone was analyzed (Table S2 in the Supplementary Appendix).
To directly test for an association between HLA-B*13:01 and the dapsone hypersensitivity syndrome as well as to assess the accuracy of the HLA imputation, we determined the HLA-B and HLA-C alleles in the 39 case patients and 78 controls included in the discovery analysis and an additional 38 case patients and 206 controls, using Roche 454 GS FLX sequencing. Both sets of controls were randomly selected from the discovery and replication samples. Of the 361 samples, 354 were successfully sequenced for HLA-B (98.1%) and 359 were successfully sequenced for HLA-C (99.4%), with coverage of at least 10 reads per exon per sample.
Although the sample from one control could not be sequenced, the concordance between the imputed and sequencing-determined genotypes of the HLA-B*13:01 allele in the 116 samples from the discovery analysis was 99%; there was only one discrepancy, in which a case patient was found to carry one copy of this allele by imputation but was not found to carry this allele on sequencing. For HLA-C*03:04, the concordance was 99%, with one discrepancy, in which a case patient was found to be a heterozygous carrier by imputation but a homozygous carrier by sequencing. Our sequencing analysis confirmed the high accuracy of the HLA imputation, particularly for HLA-B and HLA-C alleles (additional concordance data are shown in Table S3 in the Supplementary Appendix).
The replication analysis involving 37 case patients and 201 controls showed a significant genomewide association of HLA-B*13:01 with the dapsone hypersensitivity syndrome (odds ratio, 23.54; P = 4.74×10 −10 ) and HLA-C*03:04 (odds ra- 0.14 53.5 * Odds ratios are per allele. Unless otherwise indicated, P values were calculated with the use of logistic-regression analysis. The odds ratios and P values for the combined samples were adjusted for study variable. Scores on the heterogeneity index range from 0 to 100, with higher scores indicating greater heterogeneity. CI denotes confidence interval.
The tio, 5.90; P = 9.15×10 −7 ). We also observed that controlling for HLA-B*13:01 fully eliminated the effect of HLA-C*03:04 (adjusted P = 0.46) but not vice versa (adjusted P = 4.74×10 −7 ). The combined analysis of the discovery and replication samples resulted in a very strong association of HLA-B*13:01 with the dapsone hypersensitivity syndrome (odds ratio, 20.53; P = 6.84×10 −25 ), with no evidence of genetic heterogeneity between the discovery and replication samples (P = 0.74 by Cochran's Q test; I 2 = 0) ( Table 2) . A severe deviation of HLA-B*13:01 genotype frequency from HardyWeinberg equilibrium was observed in the samples from the case patients (P = 2.69×10 −7 ) ( Table 3 ). The findings in the combined sample of 76 case patients and 1034 controls were consistent with those in the discovery sample. The variants at amino acid positions 94, 95, and 145 (whose haplo type Ile94-Ile95-Leu145 defines the HLA-B*13:01 allele) were significantly associated with the dapsone hypersensitivity syndrome, but these associations were much weaker than that at HLA-B*13:01 (P = 5.38×10 −15 , P = 7.11×10 −15 , and P = 2.43×10 −19 , respectively, by an omnibus test) ( Table S4 in (Tables S1 and S4 in the Supplementary Appendix) but not vice versa. The variant encoding Leu145 was also carried by the HLA-B*13:02 haplotype, which was present only in our controls (with a frequency of 6%). Similarly, the variants encoding Ile94 and Ile95 were also carried by another HLA-B haplotype that did not show any association with the dapsone hypersensitivity syndrome (Table S5 in the Supplementary Appendix) . Taken together, these data indicate that the HLA-B*13:01 haplotype, rather than any component variant, is likely to be a susceptibility risk variant.
HLA-B*13:01 as a Risk Predictor for the Dapsone Hypersensitivity Syndrome
Analysis of the pooled discovery and replication samples showed that the HLA-B*13:01 allele was present in 86% of the case patients (65 of 76) but in only 14% of the controls (148 of 1034) ( Table 3 ). These findings suggest that the presence of HLA-B*13:01 had a sensitivity of 85.5% and a specificity of 85.7% as a risk predictor for the dapsone hyper sensitivity syndrome, with an area under the curve of 0.89 (Fig. S3 in the Supplementary Appendix). According to these results, the risk among persons carrying one copy of the HLA-B*13:01 allele is 33.6 times as high as the risk among those carrying no copies (heterozygous odds ratio) and the risk among persons carrying two copies is 100.7 times as high (homozygous odds ratio). On the basis of an estimated prevalence of the dapsone hypersensitivity syndrome of 1.4%, 8 we calculated that HLA-B*13:01 would have a positive predictive value of 7.8% and a negative predictive value of 99.8%, and 84 patients would need to be screened in order to prevent one case of the syndrome. Clinical testing for HLA-B*13:01, with persons who had positive results receiving treatment that excluded dapsone, could theoretically reduce the risk of the dapsone hypersensitivity syndrome by a factor of 7 (from 1.4% to 0.2%).
We investigated the prevalence of the HLA-B*13:01 allele in the Chinese population by evaluating 1944 healthy Chinese persons from Shandong, Yunnan, and Guangdong provinces through HLA imputation. The frequency of this allele was 3.3%, 7.1%, and 8.6% in the three provinces, respectively ( Table 3 
DISCUSSION
In this study, we found an association of HLA-B*13:01 with the dapsone hypersensitivity syndrome. HLA-B belongs to HLA class I heavy-chain paralogues that play a central role in the immune system by presenting peptides derived from the lumen of the endoplasmic reticulum. A study of HLAassociated drug reactions to abacavir has shown that small-molecule drugs can alter the peptide repertoire by specifically and noncovalently interacting with HLA class I molecules. 24 Polymorphisms at this site can markedly alter the specificity of the peptide motif. 25 Because the side chains of the peptide anchor residues provide the molecular basis for allele-specific recognition of antigenic peptides, the amino acid combination of these three unique sites of HLA-B*13:01 may play a role in the immunopathogenesis of the dapsone hypersensitivity syndrome.
The deviation of HLA-B*13:01 genotype frequency from Hardy-Weinberg equilibrium for the case patients (but not the controls) is consistent with HLA-B*13:01 as a susceptibility variant for the association with the syndrome. The strong genetic effect of HLA-B*13:01 was expected to cause an oversampling of HLA-B*13:01 in our case patients. Furthermore, only the surviving patients with the dapsone hypersensitivity syndrome were recruited in this study as the case patients; their symptoms are likely to have been relatively mild as compared with those of patients with the dapsone hypersensitivity syndrome who died before sample collection. Nonrandom sampling and the absence of patients with fatal dapsone hypersensitivity syndrome in our study may have contributed to the deviation of HLA-B*13:01 genotype frequency from Hardy-Weinberg equilibrium in the case patients.
A limitation of our study is that we did not have clinical confirmation that all our controls were free of the dapsone hypersensitivity syndrome; only 6% of them were known, on the basis of medical records, to be free of the dapsone hypersensitivity syndrome after 6 to 24 months of treatment. It is therefore possible that some of the controls actually had the dapsone hypersensitivity syndrome, and if so, this might have caused an underestimation of the risk effect of HLA-B*13:01, but any effect should be minimal, because the prevalence of the syndrome is low, and all patients with leprosy who served as controls had been cured of the disease with multidrug therapy and were therefore likely to be free of the dapsone hypersensitivity syndrome.
HLA-B*13:01 typing for dapsone-related treatments is clinically relevant. By identifying carriers of the HLA-B*13:01 allele and modifying the therapeutic regimen they receive -for example, by substituting clofazimine for dapsone in multi drug therapy for paucibacillary disease or by eliminating dapsone from multidrug therapy for multibacillary disease -the risk of the dapsone hypersensitivity syndrome could be reduced by a factor of 7 (from 1.4% to 0.2%).
However, the clinical benefit of HLA-B*13:01 typing is going to vary across populations owing to differences in the use of dapsone as treatment and in the prevalence of the dapsone hypersensitivity syndrome and HLA-B*13:01. HLA-B*13:01 is one of the most frequent members of HLA-B*13, but it is present primarily in Asian populations. Current information indicates that HLA-B*13:01 is absent in European and African populations. Among the nations with a high incidence rate of leprosy, India has the highest recorded prevalence of the HLA- In conclusion, we found that HLA-B*13:01 is a strong risk factor for the dapsone hypersensitivity syndrome in the Chinese population; this finding sheds light on the pathogenesis of the syndrome. More important, our findings may facilitate the development of HLA-B*13:01 tests for use in clinical practice to identify persons at risk for this potentially life-threatening condition and may thus improve the safety of dapsone therapy.
